n-3 PUFA supplements may significantly improve cognitive development in infants but do not improve cognitive performance in children, adults, or the elderly. n-3 PUFA intake, especially that of DHA supplements, may benefit cognitive development during infancy.

Background: Recently, emerging studies have identified that MNX1-AS1 highly expressed among variety of cancers and related with worse prognosis of cancer patients. The purpose of this study was to evaluate the relationship between MNX1-AS1 expression with clinical features and prognosis in different cancers. Methods: In this study, we searched the Web of Science, PubMed, CNKI, and Wanfang databases to find relevant studies of MNX1-AS1. Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were applied to explore the prognostic and clinical significance of MNX1-AS1. Results: A total of 9 literatures were included in this study, including 882 cancer patients. The results showed that patients with increased MNX-AS1 expression were more likely to develop lymph node metastasis (OR = 5.616, 95%CI: 3.093 - 10.199, P = 0.000) and advanced TNM stage (OR = 4.625, 95%CI: 2.366-9.040, P = 0.000). Moreover, we demonstrated that patients with high expression of MNX1-AS1 had poor OS in different cancers (HR = 1.976, 95%CI: 1.653 - 2.361, P=0.000). In addition, patients with high expression of MNX1-AS1 suffer from worse prognosis in gastric cancer (HR = 2.385, 95% CI: 1.838 - 3.094, P = 0.000) and lung cancer (HR= 1.959, 95%CI: 1.353 - 2.835, P = 0.000). Conclusions: High MNX1-AS1 expression is significantly associated with unfavorable clinical outcomes and it has the potential to serve as a prognostic biomarker in cancer patients.

No abstract

No abstract

No abstract